索拉菲尼联合阿霉素治疗晚期胰腺癌的疗效评价

目的:探讨索拉菲尼联合阿霉素治疗晚期胰腺癌的临床疗效及安全性。方法:选取晚期胰腺癌患者53例,根据治疗方案不同分为单药组(n=26)和联合组(n=27)。单药组给予阿霉素60 mg/m2,静脉滴注,每21 d给药1次,总剂量360 mg/m2;联合组在单药组基础上口服索拉菲尼400 mg,2次/d,直至患者肿瘤进展或死亡。结果:联合组患者疾病控制率(DCR)为37.04%,显著高于对照组的11.54%(P<0.05)。联合组中位总生存期和中位无进展生存期分别为6.3个月、3.3个月,单药组分别为5.4个月、2.9个月,两组比较差异有统计学意义(P<0.05)。联合组腹泻、白细胞减少发生率低于单药组,而皮疹发生率高于单药组(P<0.05)。结论:索拉菲尼联合阿霉素有助于延长晚期胰腺癌患者的总生存期和无进展生存期,且可耐受毒副反应。

Evaluation of the efficacy of sorafenib combined with adriamycin in patients with advanced pancreatic cancer

Objective:To explore the clinical efficacy and safety of sorafenib combined with adriamycin in the treatment of advanced pancreatic cancer.Methods:A total of 53 patients with advanced pancreatic cancer were divided into single drug group (n=26) and drug combination group (n=27) according to therapeutic protocols.Single drug group was treated with adriamycin 60 mg/m2,ivgtt,once every 21 d,with total dosage of 360 mg/m2.On the base of single drug group,the treatment of drug combination group was added with sorafenib 400 mg,two times 1 d,until tumor deteriorated or patients died.Results:The disease control rate (DCR) was 37.04% in drug combination group,significantly higher than that in the single drug group (11.54%,P<0.05).The median overall survival time (OS) and median progression-free survival time (PFS) were 6.3 months and 3.3 months in the drug combination group,the single drug group were 5.4 months and 2.9 months,the difference between the two groups was statistically significant (P<0.05).Compared with the single drug group,a lower occurrence rate of diarrhea and leucopenia and a higher rate of rash in the drug combination group were found (P<0.05).Conclusion:Sorafenib combined with adriamycin can help to prolong the OS and PFS of patients with advanced pancreatic cancer and tolerate toxic side effects.